Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Роль бисопролола в ведении пациентов с артериальной гипертензией
Роль бисопролола в ведении пациентов с артериальной гипертензией
Недогода С.В. Роль бисопролола в ведении пациентов с артериальной гипертензией. Системные гипертензии. 2016; 13 (3): 32–34.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
В ряде рекомендаций (NICE, JNC-8, ASH/ISH) по лечению артериальной гипертензии (АГ) β-адреноблокаторы (β-АБ) отнесены на 3–4-е место среди прочих антигипертензивных препаратов (АГП), так как результаты различных метаанализов свидетельствуют об их меньшей антигипертензивной активности в сравнении с другими классами препаратов, худшем влиянии на жесткие конечные точки (особенно у лиц старше 60 лет), повышении риска развития сахарного диабета (прежде всего в комбинации с тиазидными диуретиками), негативном влиянии на эластичность аорты. Однако «новые» β-АБ по ряду ключевых для АГП характеристик (кардиоселективность, амфифильность, длительность действия, метаболическая нейтральность и т.д.) занимают лидирующие позиции. Бисопролол может рассматриваться как препарат выбора у пациентов с АГ в сочетании с ишемической болезнью сердца (стабильной стенокардией), особенно при тенденции к увеличению частоты сердечных сокращений, у больных с хронической сердечной недостаточностью, причем он эффективен как у пожилых (старше 60 лет), так и у более молодых больных (моложе 60 лет).
Ключевые слова: артериальная гипертензия, β-адреноблокаторы, бисопролол.
Key words: arterial hypertension, b-blockers, bisoprolol.
Ключевые слова: артериальная гипертензия, β-адреноблокаторы, бисопролол.
________________________________________________
Key words: arterial hypertension, b-blockers, bisoprolol.
Полный текст
Список литературы
1. Alderman MH, Cohen H, Madhavan S. Diabetes and cardiovascular events in hypertensive patients. Hypertension 1999; 33: 1130–4.
2. Bradley HA, Wiysonge CS, Volmink JA et al. How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysi. J Hypertension 2006; 24: 2131–41.
3. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007; 369: 201–7.
4. Lindholm LH, Carlberg B, Samuelsson O. Shoud b-blockers first chouse in the treatment of primary hypertension? A meta-analisys. Lancet 2005; 366: 1545–53.
5. Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens 2006; 24: 3–10.
6. Julius S et al. Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension. Am J Cardiol 2012; 109 (5): 685–92.
7. Poulter NR, Dobson JE, Sever PS et al. Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial). J Am Coll Cardiol 2009; 54: 1154–61.
8. Okin PM et al. All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy. Eur Heart J 2010; 31: 2271–9.
9. Mengden T, Vettr W. The efficacy of bisoprolol in the treatment of hypertension. Rev Contemp Pharmacother 1997; 8: 55–67.
10. Amabile G, Serradimigni A. Comparison of bisoprolol with nifedipine for treatment of essential hypertension in the elderly: comparative double-blind tria. Eur Heart J 1987; 8 (Suppl. M): 65–9.
11. Haasis R, Bethge H. Exercise blood pressure and heart rate reduction 24 and 3 hours after drug intake in hypertensive patients following 4 weeks of trearment with bisoprolol and metoprolol: a randomized multicentre double-blind study (BISOMET). Eur Heart J 1987; 8: 103–13.
12. Buhtel FR, Berglund G, Anderson OK et al. Smoking status and cardioselective beta-blocade antihypertensive therapy: the Bisoprolol International Multicentre Study (BIMS). J Hypertens 1986; 4: 144–6.
13. Подзолков В.И., Осадчий К.К. Рациональный выбор бета-адреноблокатора для лечения артериальной гипертензии: фокус на Бисогамму. РМЖ. 2008; 16 (16): 4–8. / Podzolkov V.I., Osadchii K.K. Ratsional'nyi vybor beta-adrenoblokatora dlia lecheniia arterial'noi gipertenzii: fokus na Bisogammu. RMZh. 2008; 16 (16): 4–8. [in Russian]
14. Teresa E, Gonzdlez M, Camacho-Vazquez C, Tabuenca M. Effect of bisoprolol on left ventricular hypertrophy in essential hypertension. Cardiovasc Drugsther 1994; 8: 837–43.
15. Broekman CP, Haensel SM, Van de Ven LL, Slob AK. Bisoprolol and hypertension: effects on sexual functioning in men. J Sex Marital Ther 1992; 29: 325–31.
16. Prisant LM, Weir MR, Frishman WH et al. Self Reported Sexual Dysfunction in Men and Women Treated With Bisoprolol, Hydrochlorothiazide, Enalapril, Amlodipine, Placebo, or Bisoprolol/Hydrochlorothiazide. J Clin Hypertens (Greenwich) 1999; 1 (1): 22–6.
17. Леонова М.В. Бета-блокаторы и органопротекция при артериальной гипертонии. Клин. фармакология и терапия. 2012; 21 (3): 26–30. / Leonova M.V. Beta-blokatory i organoprotektsiia pri arterial'noi gipertonii. Klin. farmakologiia i terapiia. 2012; 21 (3): 26–30. [in Russian]
18. Brode O-E. The pharmacology of bisoprolol. Rev Contemp Pharmacother 1997; 8: 21–33.
19. Остроумова О.Д., Максимов М.Л. Возможности применения высокоселективных бета-адреноблокаторов у больных с сопутствующими заболеваниями. Consilium Medicum. 2012; 14 (1): 721–5. / Ostroumova O.D., Maksimov M.L. Vozmozhnosti primeneniia vysokoselektivnykh beta-adrenoblokatorov u bol'nykh s soputstvuiushchimi zabolevaniiami. Consilium Medicum. 2012; 14 (1): 721–5. [in Russian]
20. Janka HU et al. Influence of bisoprolol on blood glucose, glucosuria and haemoglobin AL in non–insulindependent diabetics. J Cardiovasc Pharmacol 1986; 8 (Suppl. 11): 96.
21. The Task Force on Beta-Blockers of the European Society of Cardiology. Expert consensus document on b-adrenergic receptor blockers. Eur Heart J 2004; 25: 1341–62.
22. Frishman WH, Burris Jf, Mroczek WJ et al. First–line therapy with low-dose Bisoprolol fumarate and lowe-dose Hydrochlorothiazide in patients with stage I and stage II systemic hypertension. J Clin Pharmacol 1995; 35: 182–8.
23. Семенов А.В., Кукес В.Г. Клинико-фармакологические аспекты применения бисопролола. РМЖ. 2007; 15 (15): 38–43. / Semenov A.V., Kukes V.G. Kliniko-farmakologicheskie aspekty primeneniia bisoprolola. RMZh. 2007; 15 (15): 38–43. [in Russian]
2. Bradley HA, Wiysonge CS, Volmink JA et al. How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysi. J Hypertension 2006; 24: 2131–41.
3. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007; 369: 201–7.
4. Lindholm LH, Carlberg B, Samuelsson O. Shoud b-blockers first chouse in the treatment of primary hypertension? A meta-analisys. Lancet 2005; 366: 1545–53.
5. Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens 2006; 24: 3–10.
6. Julius S et al. Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension. Am J Cardiol 2012; 109 (5): 685–92.
7. Poulter NR, Dobson JE, Sever PS et al. Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial). J Am Coll Cardiol 2009; 54: 1154–61.
8. Okin PM et al. All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy. Eur Heart J 2010; 31: 2271–9.
9. Mengden T, Vettr W. The efficacy of bisoprolol in the treatment of hypertension. Rev Contemp Pharmacother 1997; 8: 55–67.
10. Amabile G, Serradimigni A. Comparison of bisoprolol with nifedipine for treatment of essential hypertension in the elderly: comparative double-blind tria. Eur Heart J 1987; 8 (Suppl. M): 65–9.
11. Haasis R, Bethge H. Exercise blood pressure and heart rate reduction 24 and 3 hours after drug intake in hypertensive patients following 4 weeks of trearment with bisoprolol and metoprolol: a randomized multicentre double-blind study (BISOMET). Eur Heart J 1987; 8: 103–13.
12. Buhtel FR, Berglund G, Anderson OK et al. Smoking status and cardioselective beta-blocade antihypertensive therapy: the Bisoprolol International Multicentre Study (BIMS). J Hypertens 1986; 4: 144–6.
13. Podzolkov V.I., Osadchii K.K. Ratsional'nyi vybor beta-adrenoblokatora dlia lecheniia arterial'noi gipertenzii: fokus na Bisogammu. RMZh. 2008; 16 (16): 4–8. [in Russian]
14. Teresa E, Gonzdlez M, Camacho-Vazquez C, Tabuenca M. Effect of bisoprolol on left ventricular hypertrophy in essential hypertension. Cardiovasc Drugsther 1994; 8: 837–43.
15. Broekman CP, Haensel SM, Van de Ven LL, Slob AK. Bisoprolol and hypertension: effects on sexual functioning in men. J Sex Marital Ther 1992; 29: 325–31.
16. Prisant LM, Weir MR, Frishman WH et al. Self Reported Sexual Dysfunction in Men and Women Treated With Bisoprolol, Hydrochlorothiazide, Enalapril, Amlodipine, Placebo, or Bisoprolol/Hydrochlorothiazide. J Clin Hypertens (Greenwich) 1999; 1 (1): 22–6.
17. Leonova M.V. Beta-blokatory i organoprotektsiia pri arterial'noi gipertonii. Klin. farmakologiia i terapiia. 2012; 21 (3): 26–30. [in Russian]
18. Brode O-E. The pharmacology of bisoprolol. Rev Contemp Pharmacother 1997; 8: 21–33.
19. Ostroumova O.D., Maksimov M.L. Vozmozhnosti primeneniia vysokoselektivnykh beta-adrenoblokatorov u bol'nykh s soputstvuiushchimi zabolevaniiami. Consilium Medicum. 2012; 14 (1): 721–5. [in Russian]
20. Janka HU et al. Influence of bisoprolol on blood glucose, glucosuria and haemoglobin AL in non–insulindependent diabetics. J Cardiovasc Pharmacol 1986; 8 (Suppl. 11): 96.
21. The Task Force on Beta-Blockers of the European Society of Cardiology. Expert consensus document on b-adrenergic receptor blockers. Eur Heart J 2004; 25: 1341–62.
22. Frishman WH, Burris Jf, Mroczek WJ et al. First–line therapy with low-dose Bisoprolol fumarate and lowe-dose Hydrochlorothiazide in patients with stage I and stage II systemic hypertension. J Clin Pharmacol 1995; 35: 182–8.
23. Semenov A.V., Kukes V.G. Kliniko-farmakologicheskie aspekty primeneniia bisoprolola. RMZh. 2007; 15 (15): 38–43. [in Russian]
2. Bradley HA, Wiysonge CS, Volmink JA et al. How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysi. J Hypertension 2006; 24: 2131–41.
3. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007; 369: 201–7.
4. Lindholm LH, Carlberg B, Samuelsson O. Shoud b-blockers first chouse in the treatment of primary hypertension? A meta-analisys. Lancet 2005; 366: 1545–53.
5. Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens 2006; 24: 3–10.
6. Julius S et al. Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension. Am J Cardiol 2012; 109 (5): 685–92.
7. Poulter NR, Dobson JE, Sever PS et al. Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial). J Am Coll Cardiol 2009; 54: 1154–61.
8. Okin PM et al. All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy. Eur Heart J 2010; 31: 2271–9.
9. Mengden T, Vettr W. The efficacy of bisoprolol in the treatment of hypertension. Rev Contemp Pharmacother 1997; 8: 55–67.
10. Amabile G, Serradimigni A. Comparison of bisoprolol with nifedipine for treatment of essential hypertension in the elderly: comparative double-blind tria. Eur Heart J 1987; 8 (Suppl. M): 65–9.
11. Haasis R, Bethge H. Exercise blood pressure and heart rate reduction 24 and 3 hours after drug intake in hypertensive patients following 4 weeks of trearment with bisoprolol and metoprolol: a randomized multicentre double-blind study (BISOMET). Eur Heart J 1987; 8: 103–13.
12. Buhtel FR, Berglund G, Anderson OK et al. Smoking status and cardioselective beta-blocade antihypertensive therapy: the Bisoprolol International Multicentre Study (BIMS). J Hypertens 1986; 4: 144–6.
13. Подзолков В.И., Осадчий К.К. Рациональный выбор бета-адреноблокатора для лечения артериальной гипертензии: фокус на Бисогамму. РМЖ. 2008; 16 (16): 4–8. / Podzolkov V.I., Osadchii K.K. Ratsional'nyi vybor beta-adrenoblokatora dlia lecheniia arterial'noi gipertenzii: fokus na Bisogammu. RMZh. 2008; 16 (16): 4–8. [in Russian]
14. Teresa E, Gonzdlez M, Camacho-Vazquez C, Tabuenca M. Effect of bisoprolol on left ventricular hypertrophy in essential hypertension. Cardiovasc Drugsther 1994; 8: 837–43.
15. Broekman CP, Haensel SM, Van de Ven LL, Slob AK. Bisoprolol and hypertension: effects on sexual functioning in men. J Sex Marital Ther 1992; 29: 325–31.
16. Prisant LM, Weir MR, Frishman WH et al. Self Reported Sexual Dysfunction in Men and Women Treated With Bisoprolol, Hydrochlorothiazide, Enalapril, Amlodipine, Placebo, or Bisoprolol/Hydrochlorothiazide. J Clin Hypertens (Greenwich) 1999; 1 (1): 22–6.
17. Леонова М.В. Бета-блокаторы и органопротекция при артериальной гипертонии. Клин. фармакология и терапия. 2012; 21 (3): 26–30. / Leonova M.V. Beta-blokatory i organoprotektsiia pri arterial'noi gipertonii. Klin. farmakologiia i terapiia. 2012; 21 (3): 26–30. [in Russian]
18. Brode O-E. The pharmacology of bisoprolol. Rev Contemp Pharmacother 1997; 8: 21–33.
19. Остроумова О.Д., Максимов М.Л. Возможности применения высокоселективных бета-адреноблокаторов у больных с сопутствующими заболеваниями. Consilium Medicum. 2012; 14 (1): 721–5. / Ostroumova O.D., Maksimov M.L. Vozmozhnosti primeneniia vysokoselektivnykh beta-adrenoblokatorov u bol'nykh s soputstvuiushchimi zabolevaniiami. Consilium Medicum. 2012; 14 (1): 721–5. [in Russian]
20. Janka HU et al. Influence of bisoprolol on blood glucose, glucosuria and haemoglobin AL in non–insulindependent diabetics. J Cardiovasc Pharmacol 1986; 8 (Suppl. 11): 96.
21. The Task Force on Beta-Blockers of the European Society of Cardiology. Expert consensus document on b-adrenergic receptor blockers. Eur Heart J 2004; 25: 1341–62.
22. Frishman WH, Burris Jf, Mroczek WJ et al. First–line therapy with low-dose Bisoprolol fumarate and lowe-dose Hydrochlorothiazide in patients with stage I and stage II systemic hypertension. J Clin Pharmacol 1995; 35: 182–8.
23. Семенов А.В., Кукес В.Г. Клинико-фармакологические аспекты применения бисопролола. РМЖ. 2007; 15 (15): 38–43. / Semenov A.V., Kukes V.G. Kliniko-farmakologicheskie aspekty primeneniia bisoprolola. RMZh. 2007; 15 (15): 38–43. [in Russian]
________________________________________________
2. Bradley HA, Wiysonge CS, Volmink JA et al. How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysi. J Hypertension 2006; 24: 2131–41.
3. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007; 369: 201–7.
4. Lindholm LH, Carlberg B, Samuelsson O. Shoud b-blockers first chouse in the treatment of primary hypertension? A meta-analisys. Lancet 2005; 366: 1545–53.
5. Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens 2006; 24: 3–10.
6. Julius S et al. Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension. Am J Cardiol 2012; 109 (5): 685–92.
7. Poulter NR, Dobson JE, Sever PS et al. Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial). J Am Coll Cardiol 2009; 54: 1154–61.
8. Okin PM et al. All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy. Eur Heart J 2010; 31: 2271–9.
9. Mengden T, Vettr W. The efficacy of bisoprolol in the treatment of hypertension. Rev Contemp Pharmacother 1997; 8: 55–67.
10. Amabile G, Serradimigni A. Comparison of bisoprolol with nifedipine for treatment of essential hypertension in the elderly: comparative double-blind tria. Eur Heart J 1987; 8 (Suppl. M): 65–9.
11. Haasis R, Bethge H. Exercise blood pressure and heart rate reduction 24 and 3 hours after drug intake in hypertensive patients following 4 weeks of trearment with bisoprolol and metoprolol: a randomized multicentre double-blind study (BISOMET). Eur Heart J 1987; 8: 103–13.
12. Buhtel FR, Berglund G, Anderson OK et al. Smoking status and cardioselective beta-blocade antihypertensive therapy: the Bisoprolol International Multicentre Study (BIMS). J Hypertens 1986; 4: 144–6.
13. Podzolkov V.I., Osadchii K.K. Ratsional'nyi vybor beta-adrenoblokatora dlia lecheniia arterial'noi gipertenzii: fokus na Bisogammu. RMZh. 2008; 16 (16): 4–8. [in Russian]
14. Teresa E, Gonzdlez M, Camacho-Vazquez C, Tabuenca M. Effect of bisoprolol on left ventricular hypertrophy in essential hypertension. Cardiovasc Drugsther 1994; 8: 837–43.
15. Broekman CP, Haensel SM, Van de Ven LL, Slob AK. Bisoprolol and hypertension: effects on sexual functioning in men. J Sex Marital Ther 1992; 29: 325–31.
16. Prisant LM, Weir MR, Frishman WH et al. Self Reported Sexual Dysfunction in Men and Women Treated With Bisoprolol, Hydrochlorothiazide, Enalapril, Amlodipine, Placebo, or Bisoprolol/Hydrochlorothiazide. J Clin Hypertens (Greenwich) 1999; 1 (1): 22–6.
17. Leonova M.V. Beta-blokatory i organoprotektsiia pri arterial'noi gipertonii. Klin. farmakologiia i terapiia. 2012; 21 (3): 26–30. [in Russian]
18. Brode O-E. The pharmacology of bisoprolol. Rev Contemp Pharmacother 1997; 8: 21–33.
19. Ostroumova O.D., Maksimov M.L. Vozmozhnosti primeneniia vysokoselektivnykh beta-adrenoblokatorov u bol'nykh s soputstvuiushchimi zabolevaniiami. Consilium Medicum. 2012; 14 (1): 721–5. [in Russian]
20. Janka HU et al. Influence of bisoprolol on blood glucose, glucosuria and haemoglobin AL in non–insulindependent diabetics. J Cardiovasc Pharmacol 1986; 8 (Suppl. 11): 96.
21. The Task Force on Beta-Blockers of the European Society of Cardiology. Expert consensus document on b-adrenergic receptor blockers. Eur Heart J 2004; 25: 1341–62.
22. Frishman WH, Burris Jf, Mroczek WJ et al. First–line therapy with low-dose Bisoprolol fumarate and lowe-dose Hydrochlorothiazide in patients with stage I and stage II systemic hypertension. J Clin Pharmacol 1995; 35: 182–8.
23. Semenov A.V., Kukes V.G. Kliniko-farmakologicheskie aspekty primeneniia bisoprolola. RMZh. 2007; 15 (15): 38–43. [in Russian]
Авторы
С.В.Недогода
ФГБОУ ВО Волгоградский государственный медицинский университет Минздрава России. 400131, Россия, Волгоград, пл. Павших Борцов, д. 1
*nedogodasv@rambler.ru
Volgograd State Medical University of the Ministry of Health of the Russian Federation. 400131, Russian Federation, Volgograd, pl. Pavshikh Bortsov, d. 1
*nedogodasv@rambler.ru
ФГБОУ ВО Волгоградский государственный медицинский университет Минздрава России. 400131, Россия, Волгоград, пл. Павших Борцов, д. 1
*nedogodasv@rambler.ru
________________________________________________
Volgograd State Medical University of the Ministry of Health of the Russian Federation. 400131, Russian Federation, Volgograd, pl. Pavshikh Bortsov, d. 1
*nedogodasv@rambler.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.